Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Comment by SurfForWealthon Dec 09, 2003 7:42am
236 Views
Post# 6757113

RE: Gen-Probe audio

RE: Gen-Probe audioGreetings! I spent some time doing further reading at the Gen-Probe & CUR websites & reviewing the ML presentation. Some of my conclusions are (please correct me if I am wrong); CUR currently has 2 diagnostic products approved & on the market for bladder & prostate cancer detection. They are also working on further test for lung cancer. The current test involves going to a lab, undergoing a digital rectal exam (ultrasound?) which causes potential cancer cells to enter the urine, then taking a urine sample on the spot & using an amplifier & detection by microscope in the lab (1st generation test). Gen-Probe will use their existing FDA approved NAT technology for the same test but with better amplification & detection methods. They also hope to get FDA approval for their automated TIGRIS system which will significantly reduce technician requirements & speed up the process & patient throughput at much lower cost. The use of the TIGRIS ystem will be incorporated with the Gen-Probe improved uPM3 testing (2nd generation). Benefits will be better, faster & cheaper early stage cancer detection methods which are far superior on all aspects to the existing standards. Gen-Probe will pay for most if not all of the further R & D cost required to bring the products to market in about 2 1/2 years. The story looks great...tuck some shares into your portfolio & let it ride. You could lose all your money but that seems highly unlikely...even if things failed to work out you could sell as it fell....but....you could make 5-15 times your investment in 3-4 years. Good luck, Cheers!!!
Bullboard Posts